AMDL Signs 100 Strategic Cooperation Agreements in China for Its JPGreen Clinics; Gross Sales Per Each Location Could Exceed $40
January 25 2008 - 8:15AM
PR Newswire (US)
TUSTIN, Calif., Jan. 25 /PRNewswire-FirstCall/ -- AMDL, Inc.
(AMEX:ADL), headquartered in Tustin, California, with operations in
Shenzhen, Jiangxi, and Jilin China, through its wholly owned
subsidiary Jade Pharmaceutical Inc., is an international biopharma
company that, together with Jade, engages in the development,
manufacture and marketing of proprietary pharmaceutical, health
care and diagnostic products. It today announced that more than 100
individual owners of existing health spa centers in China have
signed strategic cooperation agreements with JJB, a Jade
subsidiary. The agreements allow JJB to re-brand the locations as
JPGreen anti-aging & spa clinics. JJB is the exclusive supplier
of its anti-aging product "Goodnak." The agreements follow a
January meeting at the Beijing Diaoyutai State Guesthouse that
attracted approximately 200 health spa center owners who want to
cooperate with JJB in order to expand the JPGreen centers. Frank
Zhang, Managing Director of Jade, stated that "these new strategic
cooperation agreements will allow JJB to increase the sales of the
expanding family of Goodnak anti-aging injections, capsules, creams
and spray products into the China market during 2008. Each new
clinic location is anticipated to annually contribute $400,000 to
$700,000 in gross sales per location." Mr. Gary Dreher, CEO of AMDL
noted that "these new regional Chinese strategic cooperation
relationships are significant achievements and improves Jade's
ability to grow its sales in 2008 and beyond." About Jade
Pharmaceutical: Jade has access to the fastest growing
pharmaceutical and consumer market in the world: China. AMDL,
through its subsidiaries, Jade currently manufactures large volume
injection fluids, tablets and other related products, holding
licenses for 133 products. It also manufactures 107 generic, over
the counter and supplemental pharmaceutical products under
certified Chinese Good Manufacturing Practice ('CGMP') standards.
About AMDL: More information about AMDL and its products can be
obtained at http://www.amdl.com/. Forward-Looking Statements: This
news release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Such
statements are subject to certain risks and uncertainties, and
actual circumstances, events or results may differ materially from
those projected in such forward-looking statements. The Company
cautions readers not to place undue reliance on any forward-looking
statements. The Company does not undertake, and specifically
disclaims any obligation, to update or revise such statements to
reflect new circumstances or unanticipated events as they occur.
Contact: AMDL, Inc. Gary L. Dreher President & CEO (714)
505-4460 DATASOURCE: AMDL, Inc. CONTACT: Gary L. Dreher, President
& CEO of AMDL, Inc., +1-714-505-4460 Web site:
http://www.amdl.com/
Copyright
Amdl (AMEX:ADL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amdl (AMEX:ADL)
Historical Stock Chart
From Jul 2023 to Jul 2024